Yohimbine is a potent and selective ␣ 2 -versus ␣ 1 -adrenoceptor antagonist. To date, drugs with high specificity for the ␣ 2 -adrenoceptor show marginal selectivity among the three ␣ 2 -adrenoceptor subtypes. Initial studies showed that yohimbine was about 4-and 15-fold more selective for the human ␣ 2C -adrenoceptor in comparison with the ␣ 2A -and ␣ 2B -adrenoceptors, respectively. To improve on this ␣ 2 -adrenoceptor subtype selectivity, a series of yohimbine dimers (varying from n ϭ 2 to 24 spacer atoms) were prepared and evaluated for receptor binding on human ␣ 2 -adrenoceptor subtypes expressed in Chinese hamster ovary cells. Each dimeric analog showed higher affinities for ␣ 2A -and ␣ 2C -adrenoceptor versus the ␣ 2B -adrenoceptor; and yohimbine dimers with spacers of n ϭ 2, 3, 4, 18, and 24 exhibited selectivity for the ␣ 2C -adrenoceptor. The yohimbine dimers n ϭ 3 and n ϭ 24 showed the highest potency and selectivity (32-and 82-fold. respectively) for the ␣ 2C -adrenoceptor in receptor binding and in functional studies (42-and 29-fold, respectively) measuring cAMP changes using a cell-based luciferase reporter gene assay. The dimers (n ϭ 3 and n ϭ 24) had high selectivity (Ͼ1000-fold) for the ␣ 2C -adrenoceptor compared with the three ␣ 1 -adrenoceptor subtypes. These findings demonstrate that the addition of spacer linkages to bivalent yohimbine molecules provides a successful approach to the development of ligands that are potent and highly selective for the ␣ 2C -adrenoceptor.
The lack of ␣ 2 -adrenoceptor (AR) subtype-selective antagonists has precluded clarification of the role of each subtype in various physiological and behavioral studies (MacDonald et al., 1997) . Homologous recombination strategies that lead either to gene knockouts or a substitution of a mutant receptor at the wild-type locus in the mouse genome have been developed. Using genetically engineered mouse strains it has been suggested that the ␣ 2C -AR subtype has a distinct inhibitory role in the processing of sensory information and in the control of motor and emotion-related activities in the central nervous system (Scheinin et al., 2001) . It is therefore possible that ␣ 2C -AR-selective drugs may have therapeutic value in the treatment of various neuropsychiatric disorders. In addition to the central nervous system effects associated with ␣ 2C -AR, a remarkable role of ␣ 2C -AR in vascular dysfunction has recently been discovered. The cold-induced cutaneous arterial blood vessel constriction observed in Raynaud's disease may be linked to increased reactivity of smooth muscle ␣ 2C -AR. ␣ 2C -ARs are not functionally responsive at 37°C, i.e., silent in normal regulation of the vascular function, but are activated by catecholamines at 28°C (Chotani et al., 2000) . Thus, selective blockade of these receptors by using ␣ 2C -ARselective antagonists may provide a new therapeutic intervention for the treatment of Raynaud's disease. Findings from cardiovascular studies using ␣ 2A -, ␣ 2B -, and ␣ 2C -AR knockout mice indicated that although the peripheral ␣ 2A -and ␣ 2B -AR modulate blood pressure, the ␣ 2C -AR does not play a measurable role in the control of systemic blood pressure (MacDonald et al., 1997) . This finding is consistent with the notion that an ␣ 2C -AR-selective drug may offer beneficial clinical uses with a minimal potential for systemic blood pressure effects (Rizzo et al., 2001) . ␣ 2C -AR subtype-selective antagonists will help to further elucidate the physiological roles of this receptor and may provide leads for a variety of therapeutic disorders.
The present article illustrates the identification of potent and selective human ␣ 2C -AR antagonists using the bivalent ligand approach. The term bivalent ligand (or pharmacophore dimer) is defined as a molecule that contains two pharmacophores linked through a spacer. This approach to receptor ligand design would be predicted to generate ligands that exhibit a potency that is greater than that derived from the sum of its two monovalent counterparts. The design relies on the concept that a bivalent ligand should first undergo univalent binding, followed by the binding of the second pharmacophore to a recognition site on a neighboring receptor (Portoghese, 2001) . Here, we selected the bivalent pharmacophore of yohimbine because this compound is a selective and potent ␣ 2 -AR antagonist (Bylund, 1985) . The yohimbine dimers used were evaluated on human ␣ 2A -, ␣ 2B -, and ␣ 2C -AR subtypes expressed stably in Chinese hamster ovary (CHO) cells using a radioligand binding assay. Selective yohimbine dimers were also evaluated for binding affinities on human ␣ 1A -, ␣ 1B -, and ␣ 1D -AR subtypes expressed stably in human embryonic kidney (HEK) cells. Finally, cell systems containing cDNA clones of the ␣ 2 -ARs, were used to assay agonist and antagonist agents using a CRE reporter gene functional assay. Our approach was to evaluate changes in luciferase activities, as an index of cAMP accumulations, for highly selective yohimbine dimers on human ␣ 2 -AR subtypes expressed in CHO cells.
Materials and Methods
Sources of Materials. All cell culture reagents were obtained from Invitrogen (Carlsbad, CA). Human ␣ 2A -, ␣ 2B -, and ␣ 2C -AR subtypes expressed in CHO cells were obtained from Drs. Marc Caron and Robert Lefkowitz (Duke University Medical Center, Durham, NC) and Dr. Stephen Liggett (College of Medicine, University of Cincinnati, Cincinnati, OH). Human ␣ 1A -, ␣ 1B -, and ␣ 1D -AR subtypes expressed in HEK cells were obtained from Dr. Kenneth Minneman (Department of Pharmacology, Emory University School of Medicine, Atlanta, GA). MK-912 was obtained from Merck (Rahway, NJ). Yohimbine dimers (Fig. 1) were provided by Dr. Duane D. Miller (Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN). The yohimbine dimers (n ϭ 2, 3, 4, 5, 6, and 9) were prepared as diamides by coupling the commercially available yohimbinic acid with aliphatic ␣,-diamines under standard peptide coupling condition (Zheng et al., 2000) . The procedures for the synthesis of the glycinamide derivatives (n ϭ 18 and n ϭ 24) are as described by Zheng (1999) . All the yohimbine dimers were hygroscopic and light-sensitive, and dimers, with the exception of n ϭ 18 and n ϭ 24, were provided as dihydrochloride salts and were soluble in water. The dimers n ϭ 18 and n ϭ 24, prepared as glycinamide derivatives and supplied as the free base, were dissolved in a 1:5 mixture of dimethyl sulfoxide/water. Stock solutions of 10 mM were prepared and diluted in water to appropriate concentrations for these studies. Samples and drug solutions were protected from light. Cell Culture. CHO cells stably expressing human ␣ 2A -, ␣ 2B -, and ␣ 2C -AR subtypes were grown in 150-cm 2 Corning flasks with Ham's F-12 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin (100 units/ml), and streptomycin 100 g/ml). The flasks were incubated at 37°C (5% CO 2 ). Media were changed every 48 h until the cells were confluent. Upon confluence, the cells were detached by addition of 0.05% trypsin EDTA for 3 to 5 min.
HEK cells stably expressing human ␣ 1A -, ␣ 1B -, and ␣ 1D -AR subtypes were grown in 150-cm 2 Corning flasks with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin.
The flasks were incubated at 37°C (5% CO 2 ). Media were changed every 48 h until the cells were confluent. Upon confluence, the cells were detached by gentle scraping.
Radioligand Binding Assays. Radioligand binding studies were performed in CHO cells expressing human ␣ 2A -, ␣ 2B -, and ␣ 2C -AR subtypes and HEK cells expressing human ␣ 1A -, ␣ 1B -, and ␣ 1D -AR subtypes. The detached cells were washed and centrifuged with Tris-EDTA buffer, pH 7.4, in which they were finally suspended. The competition binding assays were performed in duplicate by incubating 50,000 cells with [ 3 H]rauwolscine and [ 3 H]prazosin for the ␣ 2 -and ␣ 1 -ARs, respectively, and varying concentrations of the compounds under investigation for 1 h in a water bath at 37°C. Nonspecific binding was defined by addition of 10 M yohimbine and 10 M phentolamine for the ␣ 2 -and ␣ 1 -ARs, respectively. Cell suspensions were filtered using GF/B glass fiber filters (Whatman, Maidstone, UK) using a cell harvester (model 12-R; Brandel Inc., Gaithersburg, MD). The filter discs were washed three times with 5 ml of Tris-EDTA buffer, pH 7.4, at 4°C. The radioactivity was determined using a TriCarb 2900TR liquid scintillation counter (Packard Instrument Company, Inc., Downers Grove, IL). The displacement curves were generated using GraphPad Prism software (GraphPad Software, San Diego, CA). The displacement curves were plotted using a standard slope factor of 1.0; and the K i values of the competing ligands were determined using the equation of Cheng and Prusoff (1973) . The percentage of specific binding was determined by dividing the difference between total bound (dpm) and nonspecific bound (dpm) by the total bound (dpm).
Scatchard analyses for radioligands were determined using vary- (Bylund et al., 1998) .
Cyclic AMP Response Element-Luciferase Reporter Gene Assay. The functional responses of the yohimbine analogs in these ␣ 2 -AR subtypes were determined with the use of six copies of a cAMP response element-luciferase reporter gene construct (6 CRE-LUC, pADneo2-C6-BGL) provided by Dr. A. Himmler (Boehringer Ingelheim Research and Demonstration, Vienna, Austria) by the same transfection procedures described previously in CHO cells (Vansal and Feller, 1999) . The antagonist effects of yohimbine and the two highly selective bivalent analogs (n ϭ 3 and n ϭ 24) were examined for their concentration-dependent reversal of medetomidine on forskolin-induced cAMP levels, as assessed by luciferase activity changes in CHO cells expressing the human ␣ 2A -and ␣ 2C -AR subtypes. The compounds were tested under the following conditions: the 6 CRE-LUC plasmid (5 g/100 l of cell suspension) was transiently transfected into CHO cells expressing the ␣ 2A -and ␣ 2C -AR subtypes using electroporation, at 150 V, 70 ms, single pulse. The transfected cells were plated at a density of 50,000 cells/200 l/well in a 96-well microtiter plate and allowed to grow for 20 h. The compounds under investigation for agonist activity were added directly to the medium and allowed to incubate for 4 h. When tested for antagonist activity, the compounds were added at varying concentrations 20 min before addition of a fixed concentration of medetomidine (10 nM). Subsequently, the media were aspirated, the cells lysed, and the luciferase activity determined using a TopCount (Packard BioScience, Meriden, CT) luminometer after adding luciferin. Data were analyzed using GraphPad Prism software and expressed as a mean Ϯ S.E.M. The response produced by 5 M forskolin in each experiment was used as 100%.
Data Accumulation and Statistical Analyses. For ligand binding studies in cell lines, varying concentrations of each drug/ligand (ranging from 10 Ϫ4 -10 Ϫ11 M) were added in duplicate within each experiment, and the individual molar IC 50 values were determined using GraphPad Prism. The K i values of each ligand were determined according to the equation described by Cheng and Prusoff (1973) , and final data are presented as pK i Ϯ S.E.M. of n Ն 4 experiments. The concentration-dependent reversal of medetomidine actions on luciferase activity changes in CHO cells by yohimbine and dimers (n ϭ 3 and n ϭ 24) were determined as molar EC 50 and negative log molar effective concentration-50 (pEC 50 ) values Ϯ S.E.M. of n ϭ 3 to 4 experiments. Differences of means of binding affinities and functional responses for individual ligands on the AR subtypes were done by analysis of variance and Tukey's post hoc analysis test.
Results
Radioligand Binding Assay. Radioligand binding analyses of yohimbine and its dimeric analogs were performed in CHO cells expressing human ␣ 2A -, ␣ 2B -, and ␣ 2C -AR subtypes. The binding affinities of these dimers are presented in Table 1 . Yohimbine was about 4-and 15-fold more selective for the ␣ 2C -AR compared with the ␣ 2A -and ␣ 2B -AR, respectively (Table 1) . MK-912 was also tested as a standard because it is known to have a higher affinity for the ␣ 2C -AR subtype (Uhlen et al., 1997) . In our study MK-912 was about 14-and 3-fold more selective for the ␣ 2C -AR compared with the ␣ 2A -and ␣ 2B -AR, respectively (Table 1) . Displacement curves demonstrating the ␣ 2C -versus ␣ 2A -and ␣ 2B -AR selectivity for yohimbine are presented in Fig. 2 . The yohimbine analogs, with the exception of the dimer (n ϭ 7) on the ␣ 2A -AR, displayed significantly lower binding affinities than yohimbine on the three ␣ 2 -AR subtypes. However, the dimeric analogs show much higher affinities for the ␣ 2A -and ␣ 2C -AR subtypes versus the ␣ 2B -subtype at all spacer atom lengths (n ϭ 2 to n ϭ 24), and there are relatively small changes in the K i values for these analogs on the ␣ 2C -AR subtype. Comparison of the pK i Ϯ S.E.M. values for these bivalent yohimbine analogs on the three ␣ 2 -AR subtypes (Table 1) shows that there is at least a 6.5-fold higher binding affinity of the yohimbine analogs (n ϭ 2, 3, 4, 18, and 24) for jpet.aspetjournals.org the ␣ 2C -subtype. Binding displacement curves for the dimers n ϭ 3 and n ϭ 24 are shown in Fig. 3 . Compared with yohimbine the binding displacements curves for the selective dimers n ϭ 3 and n ϭ 24 are shifted to the right, especially for ␣ 2A -and ␣ 2B -AR subtypes. The yohimbine dimers (n ϭ 2, n ϭ 3, and n ϭ 24) possess affinities for the ␣ 2C -AR, which are 23-and 891-fold, 32-and 355-fold, and 82-and 776-fold greater than their binding to the ␣ 2A -and ␣ 2B -AR subtypes, respectively (Table 1) .
The binding affinities of yohimbine and the two bivalent selective analogs (n ϭ 3 and n ϭ 24) were determined in HEK cells expressing human ␣ 1A -, ␣ 1B -, and ␣ 1D -AR subtypes to establish the ␣ 2 -versus ␣ 1 -AR subtype selectivity of these analogs. The data given in Table 2 demonstrate that yohimbine and its two bivalent analogs bind with a low affinity to the three ␣ 1 -AR subtypes. The binding affinities of yohimbine and the n ϭ 3 and n ϭ 24 dimers for the ␣ 2C -AR subtype were at least 4400-, 1000-, and 2450-fold greater than those on the ␣ 1 -AR subtypes, respectively (Tables 1 and 2 ). These findings confirm the binding selectivity of these ligands for the ␣ 2C -AR subtype.
Cyclic AMP Response Element-Luciferase Reporter Gene Assay. Luciferase reporter gene assay experiments were conducted by adding a fixed concentration of medetomidine (10 nM) to block the cAMP-induced increases by 5 M forskolin. A concentration of medetomidine was chosen that produced at least a 50% inhibition of the forskolin response in the ␣ 2C -AR subtype expressing CHO cell lines. Controls of yohimbine and medetomidine and basal responses (solvent control) were included for comparisons. The effects of yohimbine and two bivalent analogs (n ϭ 3 and n ϭ 24) are provided graphically in Fig. 4 . As noted in the graphs, forskolin produced an increase in cAMP levels, as assessed by luciferase changes using a 6 CRE-LUC reporter gene bioassay. Concentrations of yohimbine and bivalent analogs (n ϭ 3 and n ϭ 24) were varied from 0.01 to 10 M. The conditions of incubation were as follows: the addition of yohimbine antagonist for 20 min; addition of medetomidine for 20 min; and the addition and incubation with forskolin for 4 h. The EC 50 values of the yohimbine analogs for the reversal of medetomidine action against forskolin-induced cAMP are presented in Table 3 . The results show that yohimbine and the two bivalent analogs were able to reverse the effect of medetomidine on the ␣ 2C -AR at lower concentrations than those required for reversal on the ␣ 2A -AR. Yohimbine, and its bivalent analogs, n ϭ 3 and n ϭ 24, were 10-, 42-, and 29-fold more potent at reversing the action of medetomidine on the ␣ 2C -versus the ␣ 2A -AR subtype, respectively. Although the fold differences between the ␣ 2A -and ␣ 2C -AR for these analogs are not equal in functional versus binding assays, the data of these functional studies show the same trend as binding affinities observed with these drugs on these two ␣ 2 -AR subtypes. Subtle differences between binding and functional results may arise and could be due to differences in receptor density for the two subtypes used for the study. Nevertheless the data indicate that these bivalent yohimbine dimers are highly selective ␣ 2C -AR antagonists. H]prazosin were used as the radloligands in the equilibrium competition radioligand binding assays for ␣ 2 -and ␣ 1 -ARs expressed in CHO and HEK cells; and nonspecific binding was measured in the presence of 10 M of yohimbine and 10 M phentolamine, respectively. Statistical analyses was carried out by one-way analysis of variance followed by Tukey's test. a pK 1 values for the analog on the ␣ 1A -AR subtype are significantly different from the pK i values for the analog on the ␣ 1D -AR subtype.
e pK 1 values for the analog on the ␣ 1A -AR subtype are significantly different from the pK 1 values on the ␣ 1D -subtype.
d pK 1 values for the analog on the ␣ 1B -AR subtype are significantly different from the pK 1 values for the analog on the ␣ 1A -and ␣ 1D -AR subtype.
b pK 1 values for the analog on the ␣ 1B -AR subtype are significantly different from the pK 1 values for the analog on the ␣ 1D -AR subtype.
Discussion
G protein-coupled receptors (GPCRs) known to exist as dimers are emerging at an accelerated rate (Bouvier, 2001) . GCPRs are major pharmacological targets and therefore the existence of dimers could have important implications for the development and screening of new drugs. The bivalent ligand approach has been successfully used in developing highly potent and selective ligands in a diverse set of receptor systems, such as the opioid (Portoghese et al., 1982; Portoghese, 2001 ) and serotonergic (LeBoulluec et al., 1995) receptors, two members of the seven transmembrane G protein-coupled receptor superfamily, as well as the growth factor receptor system (e.g., the thrombopoietin receptor) (Cwirla et al., 1997) . Several studies have also strengthened the possibility that ␣ 2A -and ␣ 2C -ARs can exist as dimers under normal physiological conditions (Maggio et al., 1993 (Maggio et al., , 1996 , which is supported by direct observations of ␣ 2A -AR clustering using immunomicroscopic techniques (Uhlen et al., 1995) .
There is a high level of sequence and structure homology, especially in the seven transmembrane regions of the ␣ 2 -AR subtypes; however, the extracellular loops are very diverse in terms of the amino acid compositions among the three subtypes. To date three ␣ 2 -AR subtypes, ␣ 2A , ␣ 2B , and ␣ 2C , have been classified using functional and molecular techniques. However, available antagonist ligands such as idazoxan, rauwolscine, or prazosin have at best only marginal-subtype selectivity among the three ␣ 2 -AR subtypes (MacDonald et al., 1997) . Therefore, in order to take advantage of receptor dimerization and clustering and the extracellular loop diversity among the ␣ 2 -AR subtypes, the bivalent ligand approach was used in our efforts to identify ␣ 2C -AR subtype-selective antagonists. For this purpose yohimbine was chosen as the antagonist pharmacophore and was found to be a potent and selective ␣ 2 -AR antagonist. Furthermore, our results show that yohimbine is about 4-and 15-fold more selective for the ␣ 2C -AR compared with the ␣ 2A -and ␣ 2B -AR, respectively. These findings agree with the previous work of Bylund et al. (1992) using these receptor subtypes from various sources. Also, the point of spacer attachment as an amide ester on the C-16 carboxyl of yohimbine was selected such that the ligand receptor binding interactions would not be impaired (Zheng et al., 2000) . This site of modification was also chosen, based on the report that the C-16 yohimbine-agarose conjugate is an excellent affinity chromatography matrix for large-scale micropurification of multiple ␣ 2 -AR subtypes. 
TABLE 3
Concentration-dependent effects of yohimbine and yohimbine analogs for the reversal of medetomidine effects on forskolin-Induced cAMP elevations on the ␣ 2A -and ␣ 2C -ARs expressed in Chinese hamster ovary cells EC 50 and pEC 50 were calculated using GraphPad Prism and expressed as the mean Ϯ S.E.M. of n ϭ 3 to 4 experiments. Values were determined as the effective concentration (EC 50 ) and negative log (pEC 50 ) of each yohimbine analog that reversed the effect of medetomidine on the maximum cAMP response of forskolin. In the present study, a series of bivalent yohimbine analogs with atom linker lengths of n ϭ 2 to n ϭ 24 were prepared and evaluated on the human ␣-AR subtypes. Each of the yohimbine dimers generally possessed a lower binding affinity than that of yohimbine for the ␣ 2A -and the ␣ 2C -AR subtypes. It is important to note that the dimeric yohimbine analogs show much higher affinities for the ␣ 2A -and ␣ 2C -AR subtypes versus the ␣ 2B -AR subtype at all linker lengths, and there was also a high degree of selectivity of yohimbine analogs for the ␣ 2C -AR subtype at spacers n ϭ 2, 3, 4, 18, and 24. In particular, yohimbine dimers n ϭ 3 and n ϭ 24 bound with an affinity for the ␣ 2C -AR subtype that was 32-and 355-fold and 82-and 776-fold greater than their binding to the ␣ 2A -and ␣ 2B -ARs, respectively. Furthermore, the selectivity of binding affinities and functional antagonist potencies of these two yohimbine dimers for the ␣ 2C -AR subtype were at least 1000-fold greater than those on the ␣ 1 -AR subtypes; and they were Ͼ29-fold selective in reversing the action of medetomidine on cAMP accumulations on the ␣ 2C -versus the ␣ 2A -AR subtype, respectively. In these functional studies, yohimbine was more potent than the two yohimbine analogs, but was less selective (10-fold) as an antagonist of the ␣ 2C -AR (Table 3) , and this correlates with the observed differences in the binding affinity selectivity for yohimbine versus these yohimbine analogs (Table 1) .
Results of our studies using bivalent yohimbine pharmacophores have yielded highly selective and potent ␣ 2C -AR antagonists. To our knowledge, the two bivalent analogs (n ϭ 3 and n ϭ 24) represent the most selective antagonists identified so far for the human ␣ 2C -AR versus the other ␣ 2 -AR subtypes. There are other ␣ 2C -AR-selective ligands such as MK-912 (Uhlen et al., 1997) . The yohimbine dimers n ϭ 3 and n ϭ 24 are 2.3-and 5.9-fold more selective for the ␣ 2C -versus the ␣ 2A -AR and 118-and 259-fold more selective for the ␣ 2C -versus the ␣ 2B -AR compared with MK-912 (Table 1) .
It is unclear as to the exact mechanism underlying the ␣ 2C -AR selectivity observed for these yohimbine dimers. It is possible that one pharmacophore binds to the ligand receptor site, with the second pharmacophore is binding with an adjacent site of the ligand binding pocket (shorter linkers, n ϭ 3), or with either one of the extracellular loops within the same receptor, or a ligand binding pocket on a second receptor. The latter possibility has been found in studies of bivalent pharmacophores on other GPCR systems (Portoghese, 2001) . Interactions with extracellular loops or with adjacent receptors (molecular clustering of receptors) are most likely to occur with the longer linkers (n ϭ 18 and n ϭ 24) used in our study. However, we are unable to differentiate between these three possibilities with these bivalent yohimbine analogs at the present time.
Interestingly, varying the length of the spacer atoms linking the yohimbine molecules together had only modest effects on ␣ 2C -AR affinities, whereas the binding potencies were found to vary considerably in comparison with the ␣ 2A -and ␣ 2B -AR subtypes. These findings suggest that further changes in atom spacer length, and possibly of the linker composition, may lead to the development of more potent ␣ 2C -AR subtype-selective ligands.
Taken collectively, these results indicate the following: 1) all of the yohimbine dimers evaluated have higher affinities at the ␣ 2A -and ␣ 2C -AR subtypes compared with the ␣ 2B -AR subtype; 2) five of the dimeric compounds, i.e., n ϭ 2, n ϭ 3, n ϭ 4, n ϭ 18, and n ϭ 24 have a high affinity and selectivity for the human ␣ 2C -AR subtype; 3) yohimbine dimers n ϭ 3 and n ϭ 24 represent potent and selective ␣ 2C -AR antagonists; and 4) the bivalent approach using yohimbine as a pharmacophore has been useful for developing ␣ 2C -AR-selective antagonists.
